OverviewSuggest Edit

MediWound is a biotechnology company. It is focused on developing, manufacturing and globally commercializing products that address unmet needs in the fields of burn and chronic wound management. MediWound's aim is to provide healthcare professionals and patients with its burn wound eschar removal agent NexoBrid.

TypePublic
Founded2001
HQYavne, IL
Websitemediwound.com

Latest Updates

Employees (est.) (Jul 2021)75
Share Price (Nov 2021)$3.3(+5%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at MediWound

Sharon Malka

Sharon Malka

Chief Executive Officer
Stephen T. Wills

Stephen T. Wills

Executive Chairman
Vickie R. Driver

Vickie R. Driver

Director
Boaz Gur-Lavie

Boaz Gur-Lavie

Chief Financial Officer
Sharon Kochan

Sharon Kochan

Director
Lior Rosenberg

Lior Rosenberg

Chief Medical Officer
Show more

MediWound Office Locations

MediWound has an office in Yavne
Yavne, IL (HQ)
Ha-Yarkon St 42
Show all (1)

MediWound Financials and Metrics

MediWound Revenue

Market capitalization (12-Nov-2021)

86.9m

Closing stock price (12-Nov-2021)

3.3
MediWound's current market capitalization is $86.9 m.
Show all financial metrics

MediWound Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

MediWound Online and Social Media Presence

Embed Graph

MediWound News and Updates

MediWound Reports Third Quarter 2021 Financial Results

Third Quarter Revenues of $6.4 Million; Year-to-Date 2021 Revenues Increased 21%

MediWound to Report Third Quarter 2021 Financial Results and Host a Conference Call and Webcast on November 16, 2021

YAVNE, Israel, Nov. 04, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the third qu…

MediWound Announces Peer-Reviewed Publication of EscharEx In-Vivo Head-to-Head Comparator Study in the Journal of Wound Care

EscharEx Treatment Demonstrated Superior Efficacy in Debridement of Eschar EscharEx Treatment Demonstrated Superior Efficacy in Debridement of Eschar

MediWound Reports Second Quarter Financial Results

Second Quarter Revenues of $6.1 Million - Increase of 50% Year-over-Year

MediWound Announces Positive Outcome of Interim Assessment for its EscharEx U.S. Phase 2 Adaptive Design Study

Independent Data Monitoring Committee Recommends Continuation of the Study withNo Changes to Study Sample Size
Show more

MediWound Blogs

EMA Provides Regulatory Path for Pediatric Label Extension for NexoBrid

Anticipate Submission for Label Extension in First Half 2022 YAVNE, Israel , Nov. 18, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today

MediWound to Report Second Quarter 2021 Financial Results and Host a Conference Call and Webcast on August 10, 2021

YAVNE, Israel , Aug. 02, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the second

MediWound Completes Patient Enrollment for Interim Assessment of its U.S. EscharEx Phase 2 Adaptive Design Study

MediWound Completes Patient Enrollment for Interim Assessment of its U.S. EscharEx Phase 2 Adaptive Design Study Content Import Wed, 06/09/2021 - 16:31 MediWound Completes Patient Enrollment for Interim Assessment of its U.S. EscharEx Phase 2 Adaptive Design Study June 9, 20…

MediWound to Report First Quarter 2021 Financial Results and Host a Conference Call and Webcast on May 5, 2021

MediWound to Report First Quarter 2021 Financial Results and Host a Conference Call and Webcast on May 5, 2021 Content Import Mon, 04/26/2021 - 16:21 MediWound to Report First Quarter 2021 Financial Results and Host a Conference Call and Webcast on May 5, 2021 April 26, 2021…

MediWound to Participate in Upcoming March Investment Conferences

YAVNE, Israel , Feb. 25, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will present at the following virtual investor

MediWound to Report Fourth Quarter and Fiscal 2020 Financial Results and Host a Conference Call and Webcast on February 25, 2021

YAVNE, Israel, Feb. 16, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the fourth
Show more

MediWound Frequently Asked Questions

  • When was MediWound founded?

    MediWound was founded in 2001.

  • Who are MediWound key executives?

    MediWound's key executives are Sharon Malka, Stephen T. Wills and Vickie R. Driver.

  • How many employees does MediWound have?

    MediWound has 75 employees.

  • Who are MediWound competitors?

    Competitors of MediWound include Aatru Medical, Hansa Biopharma and CuraVac.

  • Where is MediWound headquarters?

    MediWound headquarters is located at Ha-Yarkon St 42, Yavne.

  • Where are MediWound offices?

    MediWound has an office in Yavne.

  • How many offices does MediWound have?

    MediWound has 1 office.